CORCEPT THERAPEUTICS

Corcept's relacorilant extends ovarian cancer survival by 4.1 months in Phase 3 trial, cutting death risk 35%. FDA decision July 2026.

Corcept's Ovarian Cancer Drug Extends Lives by 4 Months in Pivotal Trial, Stock Whipsaws

Forge Global shareholders approve $660M Schwab acquisition at $45/share. Deal brings pre-IPO trading platform to 46M retail accounts.

BMS pays $50M upfront for Janux's tumor-activated immunotherapy, with $800M in milestones. JANX stock surges 14% on platform validation.

Intuitive Surgical beats Q4 estimates by 12% with $2.53 EPS as da Vinci 5 placements surge 74%. What the guidance implies for 2026.

Intuitive Surgical beats Q4 by 11% with $2.53 EPS, but guides 2026 procedure growth down to 13-15% as tariffs eat 1.2% of revenue.

Disney to name Iger's successor in weeks as $45.8M pay revealed. Four internal candidates compete for CEO role at $94B entertainment giant.